Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others
Authors:
Open Access
- 1 August 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (8) , e0182152
Abstract
Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma. However, besides its undesirable teratogenic side effect, its configurational instability critically limits any further therapeutic improvements of this drug. In 1999, we developed fluoro-thalidomide which is a bioisostere of thalidomide, but, in sharp contrast to the latter, it is configurationally stable and readily available in both enantiomeric forms. The biological activity of fluoro-thalidomide however, still remains virtually unstudied, with the exception that fluoro-thalidomide is not teratogenic. Herein, we report the first biological evaluation of fluoro-thalidomide in racemic and in both (R)- and (S)-enantiomerically pure forms against (in vitro) H929 cells of multiple myeloma (MM) using an annexin V assay. We demonstrate that all fluoro-thalidomides inhibited the growth of H929 MM cells without any in-vivo activation. Furthermore, we report that the enantiomeric forms of fluoro-thalidomide display different anti-tumour activities, with the (S)-enantiomer being noticeably more potent. The angiogenesis of fluoro-thalidomides is also investigated and compared to thalidomide. The data obtained in this study paves the way towards novel pharmaceutical research on fluoro-thalidomides.Keywords
Funding Information
- Japan Agency for Medical Research and Development
- Kobayashi International Scholarship Foundation
- Japan Science and Technology Agency
- Takeda Science Foundation
This publication has 71 references indexed in Scilit:
- Ripped to deathTrends in Cell Biology, 2011
- Fluorothalidomide: A Characterization of Maternal and Developmental Toxicity in Rabbits and MiceToxicological Sciences, 2011
- Self-disproportionation of enantiomers of heterocyclic compounds having a tertiary trifluoromethyl alcohol center on chromatography with a non-chiral systemJournal of Fluorine Chemistry, 2010
- Thalidomide attenuates nitric oxide‐driven angiogenesis by interacting with soluble guanylyl cyclaseBritish Journal of Pharmacology, 2009
- Synthesis and evaluation of 4-[18F]fluorothalidomide for the in vivo studies of angiogenesisNuclear Medicine and Biology, 2006
- The emerging role of poly(ADP-ribose) polymerase-1 in longevityThe International Journal of Biochemistry & Cell Biology, 2005
- Clinical Pharmacokinetics of ThalidomideClinical Pharmacokinetics, 2004
- Fluorine substituent effects (on bioactivity)Journal of Fluorine Chemistry, 2001
- (R)- and (S)-3-Fluorothalidomides: Isosteric Analogues of ThalidomideOrganic Letters, 1999
- Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450Toxicology and Applied Pharmacology, 1986